Using arsenic trioxide to eliminate HIV-1 reservoirs in patients on antiretroviral therapy
The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
This study is testing if adding arsenic trioxide to standard HIV treatment can help get rid of hidden HIV in people living with the virus.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Guangzhou 8th People's Hospital Academic / other |
| Drugs / interventions | cART |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT03980665 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and efficacy of arsenic trioxide combined with combined antiretroviral therapy (cART) in eliminating latent HIV-1 reservoirs in HIV-infected patients. The approach utilizes a shock and kill strategy, where arsenic trioxide acts as a latency reversing agent to reactivate latent HIV-1, allowing for potential eradication. The trial will monitor adverse events, HIV-1 reservoir levels, viral load, and immune responses in a cohort of 20 participants. The goal is to explore new strategies for achieving a functional cure for AIDS.
Who should consider this trial
Good fit: Ideal candidates are HIV-infected individuals who have been on HAART for over 12 months with controlled viral loads and adequate CD4+ cell counts.
Not a fit: Patients with serious chronic diseases, active infections, or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to innovative strategies for achieving a functional cure for HIV/AIDS.
How similar studies have performed: While the shock and kill strategy has been explored, the specific use of arsenic trioxide as a latency reversing agent is relatively novel and has not been extensively tested in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. HIV infection confirmed 2. Receiving HAART more than 12 months. 3. HIV viral-load \< 50 copies/ml and CD4+ cell count more than 350 cells/ul. 4. Without serious heart, lung, liver or kidney disease. 5. Participants know about the study and sign informed consent. Exclusion Criteria: 1. With serious active HBV or HCV infection or opportunistic infections 2. With serious chronic disease such as diabetes, mental illness,et al 3. History of suffering from pancreatitis during HAART. 4. Pregnant or breast-fed. 5. With poor adherence. 6. Unable to complete the follow up.
Where this trial is running
Guangzhou, Guangdong
- Guangzhou 8th People's Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Linghua Li, Doctor
- Email: llheliza@126.com
- Phone: 020-83710825
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.